期刊文献+

PTEN基因和P53基因在子宫内膜癌中的表达及意义 被引量:3

Expression and Clinical Significance of PTEN Gene and P53 Gene in Endometrial Carcinoma
原文传递
导出
摘要 目的:探讨PTEN基因和P53基因在子宫内膜癌中的表达及临床意义,为子宫内膜癌的治疗提供参考依据。方法:用免疫组化法检测50例子宫内膜癌患者PTEN基因缺失和P53基因突变情况,并分析两者与子宫内膜癌不同病理变化的相关性。结果:PTEN缺失24例,缺失率48.00%,进一步研究显示PTEN缺失与细胞分化程度和肌层浸润情况密切相关(P<0.05),P53突变32例,缺失率64.00%,并进一步研究显示P53突变与FIGO分期,细胞分化程度和肌层浸润情况密切相关(P<0.05)。结论:PTEN基因缺失和P53基因突变与子宫内膜癌发生和发展密切相关,以PTEN基因和P53基因为靶点的生物治疗在进展期内膜癌中的治疗价值值得进一步深入研究。 Objective: To study the effect of deletion of PTEN Gene and mutation of P53 gene on endometrial carcinoma, provides the reference for the treatment of uterine endometrial carcinoma. Methods: Immunohistochemistry was used to deletion of PTEN Gene and mutation of P53 gene, and analyze both with endometrial cancer pathology. Results: Deletion of PTEN Gene in 24 cases, the loss rate of 48% Further study showed that the expression of deletion of PTEN gene significantly correlated with cell differentiation and myometrial invasion(P〈0.05), mutation of P53 gene the mutation being64.00%, and Further study showed that the mutation of P53 gene significantly correlated with FIGO stage, cell differentiation and myometrial invasion situation(P〈0.05). Conclusion: Deletion of PTEN gene and mutation of P53 gene, was associated with endometrial carcinoma development. The PTEN gene and P53 gene as the therapeutic value of target of biological treatment in the progression of endometrial carcinoma is worthy of further study.
机构地区 解放军第
出处 《现代生物医学进展》 CAS 2014年第14期2628-2631,共4页 Progress in Modern Biomedicine
基金 国家自然科学基金项目(30872749)
关键词 PTEN P53 子宫内膜癌 PTEN P53 Endometrial carcinoma
  • 相关文献

参考文献2

二级参考文献28

共引文献5

同被引文献43

  • 1胡莉.PTEN和P53在子宫内膜癌中的表达及意义[J].中国老年学杂志,2014,34(11):2937-2939. 被引量:2
  • 2Golsteyn RM, Schultz SJ, Bartek J, et al. Cell cycle analysis and chromosomal localization of human Plkl, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae CdcS[J]. J Cell Scl, 1994, 107(Pt 6): 1509-1517.
  • 3Craig SN, Wyatt MD, Mclnnes C. Current assessment of polo-like kinases as anti-tumor drug targets [J]. Expert Opin Drug Discov, 2014, 9(7): 773-789.
  • 4Gjertsen BT, SchSffski P. Discovery and development of the Polo- like kinase inhibitor volasertib in cancer therapy [J]. Leukemia, 2015, 29(1): 11-19.
  • 5Holland AJ, Cleveland DW. Polo-like kinase 4 inhibition: a strategy for cancer therapy?[J]. Cancer Cell, 2014, 26(2): 151-153.
  • 6Zhang XG, Lu XF, Jiao XM, et al. PLK1 gene suppresses cell inva-sion of undifferentiated thyroid carcinoma through the inhibition of CD44v6, MMP-2 and MMP-9[J]. Exp Ther Med, 2012, 4(6): 1005- 1009.
  • 7Zhao CL, Ju JY, Gao W, et al. Downregulation of PLK1 by RNAi attenuates the tumorigenicity of esophageal squamons cell carci- noma cells via promoting apoptosis and inhibiting angiagenesis [J]. Neoplasma, 2015, 62(5): 748-755.
  • 8McCarroll JA, Dwarte T, Baigude H, et al. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer[J]. Oncotarget, 2015, 6 (14): 12020-12034.
  • 9Homing JL, Sahoo SK, Vijayaraghavalu S, ct al. 3-D tumor model for in vitro evaluation of anticancer drugs [J]. Mol Pharm, 2008, 5 (5): 849-862.
  • 10Bittinger S, Alexiadis M, Fuller PJ. Expression status and muta- tional analysis of the PTEN and PI3K subunit genes in ovarian granulosa cell tumors [J]. Int J Gynecol Cancer, 2009, 19(3): 339- 342.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部